Legis Daily

Ensuring Access to Lower-Cost Medicines for Seniors Act

USA118th CongressS-2129| Senate 
| Updated: 6/22/2023
James Lankford

James Lankford

Republican Senator

Oklahoma

Cosponsors (5)
Margaret Wood Hassan (Democratic)Rand Paul (Republican)Michael F. Bennet (Democratic)John Cornyn (Republican)Robert Menendez (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Ensuring Access to Lower-Cost Medicines for Seniors Act This bill requires prescription drug plans under the Medicare prescription drug benefit to include generic drugs and biosimilars on their formularies. Specifically, the bill requires plans that use formularies to include generic drugs and biosimilars on the formularies and without any requirements (e.g., prior authorization requirements) that are more restrictive as compared to those for brand-name drugs and biologics. Plans that use cost-sharing tiers must also have specific tiers for generic drugs and biosimilars, in accordance with certain limitations.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jun 22, 2023
Introduced in Senate
Jun 22, 2023
Read twice and referred to the Committee on Finance.
Dec 17, 2024

Latest Companion Bill Action

HR 118-5461
Referred to the Subcommittee on Health.
  • June 22, 2023
    Introduced in Senate


  • June 22, 2023
    Read twice and referred to the Committee on Finance.


  • December 17, 2024

    Latest Companion Bill Action

    HR 118-5461
    Referred to the Subcommittee on Health.

Health

Ensuring Access to Lower-Cost Medicines for Seniors Act

USA118th CongressS-2129| Senate 
| Updated: 6/22/2023
Ensuring Access to Lower-Cost Medicines for Seniors Act This bill requires prescription drug plans under the Medicare prescription drug benefit to include generic drugs and biosimilars on their formularies. Specifically, the bill requires plans that use formularies to include generic drugs and biosimilars on the formularies and without any requirements (e.g., prior authorization requirements) that are more restrictive as compared to those for brand-name drugs and biologics. Plans that use cost-sharing tiers must also have specific tiers for generic drugs and biosimilars, in accordance with certain limitations.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jun 22, 2023
Introduced in Senate
Jun 22, 2023
Read twice and referred to the Committee on Finance.
Dec 17, 2024

Latest Companion Bill Action

HR 118-5461
Referred to the Subcommittee on Health.
  • June 22, 2023
    Introduced in Senate


  • June 22, 2023
    Read twice and referred to the Committee on Finance.


  • December 17, 2024

    Latest Companion Bill Action

    HR 118-5461
    Referred to the Subcommittee on Health.
James Lankford

James Lankford

Republican Senator

Oklahoma

Cosponsors (5)
Margaret Wood Hassan (Democratic)Rand Paul (Republican)Michael F. Bennet (Democratic)John Cornyn (Republican)Robert Menendez (Democratic)

Finance Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted